Shilpa Medicare Commissions Integrated ADC Drug Substance Facility in India for End-to-End CDMO Services

Integrated antibody-drug conjugate manufacturing at commercial scale remains scarce globally, and Shilpa Biologicals has now commissioned one of the few such facilities in India capable of handling end-to-end ADC Drug Substance development and production. The move positions the Shilpa Medicare subsidiary within a narrow cohort of Indian CDMOs equipped for the full ADC manufacturing chain.

ADC Drug Substance production demands containment infrastructure, conjugation chemistry capability, and GMP-compliant bioanalytical controls that most biologics sites are not configured to support simultaneously. Facilities must satisfy the overlapping requirements of cytotoxic handling, linker-payload synthesis, and biologics process validation, a combination that has historically concentrated ADC manufacturing in a handful of Western and Japanese sites.

For QA directors and regulatory leads evaluating supply chain diversification, the facility's integrated design is the operative detail. End-to-end Drug Substance capability under one roof reduces inter-site transfer risk, simplifies batch record continuity, and narrows the regulatory surface area across 21 CFR Part 211 and ICH Q10 quality system requirements when filing for US or EU market access. It also compresses the technology transfer timeline for sponsors looking to qualify an alternate or primary CDMO site.

India's CDMO sector has expanded steadily in small-molecule generics and standard biologics, but complex modalities such as ADCs have remained underrepresented in domestic manufacturing capacity. Shilpa Biologicals' commissioning adds a credentialed option at a time when global ADC pipelines are accelerating and sponsor companies are actively seeking geographically diversified manufacturing networks following supply disruptions earlier this decade.

The facility's readiness for regulatory inspection and its performance across process validation batches will determine how quickly it can be qualified into active sponsor programs.

Source: Media4Growth via Indian Pharma Post, 24 June 2026.